Sharon A Chung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9760866/publications.pdf

Version: 2024-02-01

43 papers 3,923 citations

257429 24 h-index 276858
41
g-index

44 all docs

44 docs citations

times ranked

44

4799 citing authors

#	Article	IF	CITATIONS
1	Association of Systemic Lupus Erythematosus with <i>C8orf13–BLK</i> and <i>ITGAM–ITGAX</i> . New England Journal of Medicine, 2008, 358, 900-909.	27.0	848
2	A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nature Genetics, 2009, 41, 1228-1233.	21.4	729
3	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody†Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1366-1383.	5.6	249
4	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis and Rheumatology, 2021, 73, 1349-1365.	5 . 6	231
5	Differential Genetic Associations for Systemic Lupus Erythematosus Based on Anti–dsDNA Autoantibody Production. PLoS Genetics, 2011, 7, e1001323.	3.5	206
6	Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus. PLoS Genetics, 2008, 4, e1000084.	3 . 5	180
7	Risk Alleles for Systemic Lupus Erythematosus in a Large Case-Control Collection and Associations with Clinical Subphenotypes. PLoS Genetics, 2011, 7, e1001311.	3.5	154
8	A Comprehensive Analysis of Shared Loci between Systemic Lupus Erythematosus (SLE) and Sixteen Autoimmune Diseases Reveals Limited Genetic Overlap. PLoS Genetics, 2011, 7, e1002406.	3 . 5	148
9	Lupus Nephritis Susceptibility Loci in Women with Systemic Lupus Erythematosus. Journal of the American Society of Nephrology: JASN, 2014, 25, 2859-2870.	6.1	117
10	High-Density SNP Screening of the Major Histocompatibility Complex in Systemic Lupus Erythematosus Demonstrates Strong Evidence for Independent Susceptibility Regions. PLoS Genetics, 2009, 5, e1000696.	3 . 5	109
11	Microscopic Polyangiitis. Rheumatic Disease Clinics of North America, 2010, 36, 545-558.	1.9	106
12	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody‑Associated Vasculitis. Arthritis Care and Research, 2021, 73, 1088-1105.	3.4	90
13	<i>PTPN22</i> : Its role in SLE and autoimmunity. Autoimmunity, 2007, 40, 582-590.	2.6	77
14	Analysis of pulmonary features and treatment approaches in the COPA syndrome. ERJ Open Research, 2018, 4, 00017-2018.	2.6	71
15	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care and Research, 2021, 73, 1071-1087.	3.4	61
16	Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses. Lupus Science and Medicine, 2016, 3, e000183.	2.7	54
17	DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity. Lupus Science and Medicine, 2018, 5, e000285.	2.7	52
18	Genome-Wide Assessment of Differential DNA Methylation Associated with Autoantibody Production in Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0129813.	2.5	51

#	Article	IF	CITATIONS
19	Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients. PLoS ONE, 2018, 13, e0199003.	2.5	46
20	A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nature Communications, 2019, 10, 3902.	12.8	39
21	Sequenceâ€Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i> Arthritis and Rheumatology, 2021, 73, 512-519.	5.6	34
22	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis and Rheumatology, 2021, 73, 1384-1393.	5.6	32
23	Advances in the use of biologic agents for the treatment of systemic vasculitis. Current Opinion in Rheumatology, 2009, 21, 3-9.	4.3	31
24	European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 60, 2448-2456.	6.7	27
25	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
26	Primary Angiitis of the Central Nervous System. Rheumatic Disease Clinics of North America, 2017, 43, 503-518.	1.9	24
27	Giant Cell Arteritis: A Systematic Review and Metaâ€Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 429-441.	2.1	20
28	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care and Research, 2021, 73, 1061-1070.	3.4	15
29	Rare variants, autoimmune disease, and arthritis. Current Opinion in Rheumatology, 2016, 28, 346-351.	4.3	13
30	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis Care and Research, 2022, 74, 538-548.	3.4	13
31	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease. Arthritis and Rheumatology, 2022, 74, 586-596.	5.6	13
32	Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Metaâ€Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 101-110.	2.1	12
33	Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Metaâ€Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 196-205.	2.1	10
34	Takayasu Arteritis: a Systematic Review and Metaâ€Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 80-90.	2.1	9
35	Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 91-100.	2.1	6
36	Current Treatment of Cryoglobulinemic Vasculitis. Current Treatment Options in Rheumatology, 2016, 2, 213-224.	1.4	5

3

#	Article	IF	Citations
37	Dynamics of Methylation of <scp>CpG</scp> Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort. Arthritis and Rheumatology, 2022, 74, 1676-1686.	5.6	5
38	Endovascular Therapy for Intracranial Giant Cell Arteritis. Clinical Neuroradiology, 2022, , 1.	1.9	4
39	Neurological manifestations of polyarteritis nodosa: a tour of the neuroaxis by case series. BMC Neurology, 2021, 21, 205.	1.8	3
40	Kawasaki Disease: A Systematic Review and Metaâ€Analysis of Benefits and Harms of Common Treatments. ACR Open Rheumatology, 2021, 3, 671-683.	2.1	2
41	149â€Network-based analysis of clinical and molecular data in a multiethnic lupus cohort identifies molecular associations with serological manifestations. , 2019, , .		O
42	Reply. Arthritis and Rheumatology, 2022, 74, 545-546.	5.6	0
43	The Right Frame. Journal of Hospital Medicine, 2019, 14, 246.	1.4	O